There are currently no published studies on the OWise app that report patient health outcomes.
Patients reported positive experiences of using the OWise app.
Whether the OWise app is cost saving or not is uncertain due to the lack of directly applicable cost and outcome data.
What were we asked to look at?
We were asked to provide a high level overview of the OWise app.
The OWise app is designed for use throughout the patient journey, in conjunction with standard treatments for breast cancer, as a replacement for paper-based support tools. OWise can be accessed as an app on smartphones and tablets, or through a website (http://www.owise.uk/).
The OWise app is CE marked as a ‘medical device class 1’ (low-risk device). The OWise app and website (‘OWise app’) are synchronised so that patient information is up-to-date, regardless of how or where patients access it.
Why is this important?
In Scotland, breast cancer is the most commonly diagnosed cancer in women: in 2017 there were 4,706 new diagnoses. Unlike other PRO-generating apps or systems, the OWise app is freely available to patients and the NHS in Scotland. In the case of the beta-version currently being piloted in NHS Lothian, the OWise app is also uniquely able to feed PRO data directly into the TrakCare® electronic patient Record system where it can be accessed by the relevant clinical team.
The OWise app can be used at multiple points in the patient care pathway to replace, complement, or expand on, current paper-based tools, for example, as a replacement for paper-based chemotherapy diaries for recording side-effects and symptoms during treatment.
Px HealthCare, manufacturer of the technology.